User login
Key clinical point: Pancrelipase improves stool consistency and frequency and coefficient of fat absorption (CFA) in patients with chronic pancreatitis with moderate to severe exocrine pancreatic insufficiency (EPI).
Major finding: Higher number of patients reported decreased stool frequency at week 1 with pancrelipase vs. placebo (72% vs. 38%; P less than .001). Mean change in CFA from baseline was significantly greater with pancrelipase vs. placebo (24.7% vs. 6.4%; P less than .001). Improvements in stool consistency (P = .03) and frequency (P less than .001) correlated with CFA improvement. Symptom improvements persisted over 52 weeks of treatment.
Study details: A pooled study of 2 randomized double-blind trials including patients with chronic pancreatitis and EPI, who received either pancrelipase (n = 59) or placebo (n = 57). Thirty-four patients received open-label pancrelipase treatment for 51 weeks in another trial.
Disclosures: The editorial support for this study was funded by AbbVie. The authors reported no conflicts of interest.
Source: Barkin JA et al. Pancreas. 2021 Feb 1. doi: 10.1097/MPA.0000000000001733.
Key clinical point: Pancrelipase improves stool consistency and frequency and coefficient of fat absorption (CFA) in patients with chronic pancreatitis with moderate to severe exocrine pancreatic insufficiency (EPI).
Major finding: Higher number of patients reported decreased stool frequency at week 1 with pancrelipase vs. placebo (72% vs. 38%; P less than .001). Mean change in CFA from baseline was significantly greater with pancrelipase vs. placebo (24.7% vs. 6.4%; P less than .001). Improvements in stool consistency (P = .03) and frequency (P less than .001) correlated with CFA improvement. Symptom improvements persisted over 52 weeks of treatment.
Study details: A pooled study of 2 randomized double-blind trials including patients with chronic pancreatitis and EPI, who received either pancrelipase (n = 59) or placebo (n = 57). Thirty-four patients received open-label pancrelipase treatment for 51 weeks in another trial.
Disclosures: The editorial support for this study was funded by AbbVie. The authors reported no conflicts of interest.
Source: Barkin JA et al. Pancreas. 2021 Feb 1. doi: 10.1097/MPA.0000000000001733.
Key clinical point: Pancrelipase improves stool consistency and frequency and coefficient of fat absorption (CFA) in patients with chronic pancreatitis with moderate to severe exocrine pancreatic insufficiency (EPI).
Major finding: Higher number of patients reported decreased stool frequency at week 1 with pancrelipase vs. placebo (72% vs. 38%; P less than .001). Mean change in CFA from baseline was significantly greater with pancrelipase vs. placebo (24.7% vs. 6.4%; P less than .001). Improvements in stool consistency (P = .03) and frequency (P less than .001) correlated with CFA improvement. Symptom improvements persisted over 52 weeks of treatment.
Study details: A pooled study of 2 randomized double-blind trials including patients with chronic pancreatitis and EPI, who received either pancrelipase (n = 59) or placebo (n = 57). Thirty-four patients received open-label pancrelipase treatment for 51 weeks in another trial.
Disclosures: The editorial support for this study was funded by AbbVie. The authors reported no conflicts of interest.
Source: Barkin JA et al. Pancreas. 2021 Feb 1. doi: 10.1097/MPA.0000000000001733.